Extinction models for cancer stem cell therapy

Mathematical Biosciences

Volumn 234, Issue 2, 2011, Pages 132-146

  Sehl, Mary ^a   Zhou, Hua ^b   Sinsheimer, Janet S ^a,c   Lange, Kenneth L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Birth death process; Cancer; Extinction probability; Finite Fourier transform; Stem cells; Stochastic simulation

Indexed keywords

BIRTH-DEATH PROCESS; CANCER; EXTINCTION PROBABILITY; FINITE FOURIER TRANSFORM; STOCHASTIC SIMULATIONS;

ASYMPTOTIC ANALYSIS; CELL CULTURE; CELL PROLIFERATION; COMPUTER SIMULATION; DISEASES; EIGENVALUES AND EIGENFUNCTIONS; MARKOV PROCESSES; MATHEMATICAL TRANSFORMATIONS; STATISTICS; STOCHASTIC MODELS; STOCHASTIC SYSTEMS;

STEM CELLS;

CANCER; CELL ORGANELLE; FOURIER TRANSFORM; MARKOV CHAIN; NUMERICAL MODEL; PROBABILITY; STATISTICAL ANALYSIS; STOCHASTICITY;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CANCER STEM CELL; CANCER THERAPY; CELL FATE; CELL KILLING; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; FOURIER TRANSFORMATION; MATHEMATICAL COMPUTING; PROBABILITY; STATISTICAL DISTRIBUTION; STOCHASTIC MODEL;

CELL DEATH; COMPUTER SIMULATION; HUMANS; MARKOV CHAINS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; STOCHASTIC PROCESSES;

EID: 82255178996     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2011.09.005     Document Type: Article

References (71)

1. Abkowitz J.L., Catlin S.N., McCallie M.T., Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 2002, 100:2665.
2. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983.
3. Ambrosi D., Mollicab F. On the mechanics of a growing tumor. Int. J. Eng. Sci. 2002, 40:1297.
4. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756.
5. Bao S. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008, 68:6043.
6. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730.
7. Butler E., Lichtman M.A., Coller B.S., Kipps T.J., Seligsohn U. Williams Hematology 2001, McGraw-Hill, New York. Sixth ed.
8. Cao Y., Gillespie D.T., Petzold L.R. Efficient step size selection for the tau-leaping simulation method. J. Chem. Phys. 2006, 124:1.
9. Casciari J.J., Sotirchos S.V., Sutherland R.M. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J. Cell. Physiol. 1992, 151:386.
10. Caussinus E., Gonzalez C. Induction of tumour growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat. Genet. 2005, 37:1125.
11. Cheshier S.H., Morrison S.J., Liao X., Weissman I.L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 1999, 96:3120.
12. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Neoplasia 2006, 107:4532.
13. Cox C.V., Everly R.S., Oakhill A., et al. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919.
14. Dingli D., Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006, 24:2603.
15. Dorman K.S., Kaplan A.H., Lange K.L., Sinsheimer J.S. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1?. J. Acquir. Immune Defic. Syndr. 2000, 25:398.
16. Dorman K., Sinsheimer J.S., Lange K. In the garden of branching processes. SIAM Rev. 2004, 46:222.
17. Eckfeldt C.E., Mendenhall E.M., Verfaillie C.M. The molecular repertoire of the 'almighty' stem cell. Nat. Rev. Mol. Cell. Bio. 2005, 6:726.
18. Feller W. An Introduction to Probability Theory and Its Applications 1968, John Wiley & Sons, Inc., New York.
19. Feller N., van der Pol M.A., van Stijn A., et al. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukemia. Leukemia 2004, 18:1380.
20. Ferguson T.S. A Course in Large Sample Theory 1996, Chapman & Hall/CRC, New York.
21. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1977, 63:125.
22. Gatenby R.A., Gawlinski E.T. A reaction-diffusion model of cancer invasion. Cancer Res. 1996, 56:5745.
23. Gillespie D.T. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. J. Comput. Phys. 1976, 22:403.
24. Gillespie D.T. Exact stochastic simulation of coupled chemical reactions. J. Phys. Chem. 1977, 81:2340.
25. Gillespie D.T. Approximate accelerated stochastic simulation of chemically reacting systems. J. Chem. Phys. 2001, 115:1716.
26. Goldie J.H., Coldman A.J. Quantitative model for multiple levels of drug resistance in clinical tumors. Cancer Treat Rep. 1983, 67:923.
27. Graham R.L., Knuth D.E., Patashnik O. Concrete Mathematics 1989, Addison-Wesley Publishing Company, Menlo Park, CA.
28. Grimmett G.R., Stirzaker D.R. Probability and Random Processes 1992, Clarendon Press, Oxford.
29. Guzman M.L., Rossi R.M., Karnischky L. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163.
30. Guzman M.L., Neering S.J., Upchurch D., et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301.
31. Harris T.E. The Theory of Branching Processes 1989, Dover Publications, Inc., New York.
32. Henrici P. Fast Fourier methods in computational complex analysis. SIAM Rev. 1979, 21:481.
33. Higham D.J. Modeling and simulating chemical reactions. SIAM Rev. 2008, 50:347.
34. Holyoake T.L., Jiang X., Jorgensen H.G., et al. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 2001, 97:720.
35. Ismail M.E.H., Letessier J., Valent G. Birth and death processes with absorption. Internat. J Math. Math. Sci. 1992, 15:469.
36. Jagers P., Klebaner F.C., Sagitov S. On the path to extinction. Proc. Nat. Acad. Sci. 2007, 104:6107.
37. Jordan C.T. Can we finally target the leukemic stem cells?. Best Pract. Res. Clin. Haematol. 2008, 21:615.
38. Rosen J.M., Jordan C.T. The increasing complexity of the stem cell paradigm. Science 2009, 324:1670.
39. Karlin S., McGregor J. Linear growth birth and death processes. J. Math. Mech. 1958, 7:643.
40. Karlin S., Taylor H. A First Course in Stochastic Processes 1975, Elsevier, San Diego.
41. Kavalerchik E., Goff D., Jamieson C.H.M. Chronic myeloid leukemia stem cells. J. Clin. Oncol. 2008, 26:2911.
42. Kimmel M., Axelrod D.E. Branching Processes in Biology 2002, Springer-Verlag, New York.
43. Komarova N.L., Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 2005, 102:9714.
44. Lange K.L. Numerical Analysis for Statisticians 1999, Springer-Verlag, New York.
45. Lange K.L. Applied Probability 2003, Springer-Verlag, New York.
46. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645.
47. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138:286.
48. Martinez-Agosto J.A., Mikkola H.K.A., Hartenstein V., Banerjee U. The hematopoietic stem cell and its niche: a comparative view. Genes Dev. 2007, 21:3044.
49. Matsui W., Hugg C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 2004, 103:2332.
50. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267.
51. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068.
52. O'Brien C.A., Pollett A., Gallinger S., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106.
53. Okamoto O.K., Perez J.F. Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis. Expert Rev. Mol. Diagn. 2008, 8:387.
54. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895.
55. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 2007, 104:973.
56. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells 2008, 456:593.
57. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105.
58. Ruzankina Y., Pinzon-Guzman C., Asare A., et al. Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell. 2007, 1:113.
59. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiation human melanomas. Nature 2008, 451:345.
60. Sehl M.E., Alekseyenko A.L., Lange K.L. Accurate stochastic simulation via the step anticipation τ-leaping (SAL) algorithm. J. Comput. Biol. 2009, 16:1195.
61. Sehl M.E., Sinsheimer J.S., Zhou H., Lange K.L. Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res. 2009, 69:9481.
62. Shepard D.M., Ferris M.C., Olivera G.H., Mackie T.R. Optimizing the delivery of radiation therapy to cancer patients. SIAM Rev. 1999, 41:721.
63. Shih I., Wang T. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res. 2007, 67:1879.
64. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396.
65. Suva M., Riggi N., Stehle J., et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res. 2009, 69:1776.
66. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 2006, 66:1883.
67. Wilkinson D.J. Stochastic Modelling for Systems Biology 2006, Chapman & Hall/CRC, Boca Raton, FL.
68. Xin L., Lawson D.A., Witte O.N. The Sca-1 cell surface marker enriches for a prostate-regenerating cell sub-population that can initiate prostate tumorigenesis. Proc. Natl. Acad. Sci. USA 2005, 102:6942.
69. Xu Q., Simpson S.E., Scialla T.J., Bagg A., Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003, 102:972.
70. Yilmaz O.H., Valdez R., Theisen B.K., Guo W., Ferguson D.O., Wu H., Morrison S.J. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475.
71. Yilmaz O.H., Morrison S.J. The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells Mol. Dis. 2008, 41:73.